BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:REGN17372 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of REGN17372\, from ClinicalTrials.gov estim
 ates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07455851-3163@assetmemo.bio
DTSTAMP:20261121T004540Z
DTSTART;VALUE=DATE:20330930
DTEND;VALUE=DATE:20331001
SUMMARY:REGN17372: Phase 1/2 readout est. (NCT07455851)
DESCRIPTION:REGN17372\, phase 1/2\, Multiple Myeloma.\nStudy: A Trial to St
 udy if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult 
 Participants With Relapsed/Refractory Multiple Myeloma\nEstimated primary 
 completion: 30 September 2033. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/regn17372#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07455851
URL:https://assetmemo.bio/drug/regn17372#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
